Table 3.
Treatment counts among patients with ≥ 5 years of follow-up (n = 335)
| Treatment, n (%) | Months 1–6 |
Months 7–12 |
Months 13–18 | Months 19–24 | Months 25–30 | Months 31–36 | Months 37–42 | Months 43–48 | Months 49–54 | Months 55–60 |
|---|---|---|---|---|---|---|---|---|---|---|
| NSAIDs | 76 (22.7) | 69 (20.6) | 71 (21.2) | 58 (17.3) | 55 (16.4) | 54 (16.1) | 59 (17.6) | 63 (18.8) | 50 (14.9) | 54 (16.1) |
| Antimalarials | 171 (51.0) | 160 (47.8) | 150 (44.8) | 157 (46.9) | 158 (47.2) | 146 (43.6) | 151 (45.1) | 147 (43.9) | 144 (43.0) | 136 (40.6) |
| Immunosuppressants | 109 (32.5) | 105 (31.3) | 103 (30.7) | 94 (28.1) | 91 (27.2) | 85 (25.4) | 82 (24.5) | 78 (23.3) | 76 (22.7) | 76 (22.7) |
| Methotrexate | 30 (9.0) | 28 (8.4) | 26 (7.8) | 22 (6.6) | 20 (6.0) | 16 (4.8) | 15 (4.5) | 15 (4.5) | 15 (4.5) | 15 (4.5) |
| Mycophenolatea | 56 (16.7) | 50 (14.9) | 54 (16.1) | 54 (16.1) | 51 (15.2) | 47 (14.0) | 42 (12.5) | 44 (13.1) | 44 (13.1) | 44 (13.1) |
| Cyclophosphamide | 11 (3.3) | 7 (2.1) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 1 (0.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Azathioprine | 22 (6.6) | 26 (7.8) | 27 (8.1) | 23 (6.9) | 23 (6.9) | 26 (7.8) | 25 (7.5) | 20 (6.0) | 19 (5.7) | 20 (6.0) |
| Biologics | 10 (3.0) | 10 (3.0) | 10 (3.0) | 11 (3.3) | 9 (2.7) | 9 (2.7) | 7 (2.1) | 9 (2.7) | 7 (2.1) | 8 (2.4) |
| Belimumab | 9 (2.7) | 9 (2.7) | 8 (2.4) | 8 (2.4) | 8 (2.4) | 7 (2.1) | 7 (2.1) | 6 (1.8) | 5 (1.5) | 5 (1.5) |
| Rituximab | 1 (0.3) | 1 (0.3) | 2 (0.6) | 3 (0.9) | 1 (0.3) | 2 (0.6) | 0 (0.0) | 3 (0.9) | 2 (0.6) | 3 (0.9) |
| ACE inhibitors/ARBs | 145 (43.3) | 142 (42.4) | 136 (40.6) | 149 (44.5) | 141 (42.1) | 145 (43.3) | 144 (43.0) | 137 (40.9) | 141 (42.1) | 145 (43.3) |
| Corticosteroids | 201 (60.0) | 181 (54.0) | 189 (56.4) | 189 (56.4) | 165 (49.3) | 175 (52.2) | 171 (51.0) | 172 (51.3) | 158 (47.2) | 162 (48.4) |
| IV | 78 (23.3) | 72 (21.5) | 66 (19.7) | 86 (25.7) | 57 (17.0) | 78 (23.3) | 79 (23.6) | 69 (20.6) | 62 (18.5) | 68 (20.3) |
| Oral | 174 (51.9) | 145 (43.3) | 155 (46.3) | 155 (46.3) | 138 (41.2) | 131 (39.1) | 131 (39.1) | 135 (40.3) | 126 (37.6) | 132 (39.4) |
| ≥ 5 mg/dayb | 163 (93.7) | 136 (93.8) | 141 (91.0) | 142 (91.6) | 126 (91.3) | 121 (92.4) | 119 (90.8) | 121 (89.6) | 113 (89.7) | 119 (90.2) |
| ≥ 7.5 mg/dayb | 141 (81.0) | 108 (74.5) | 112 (72.3) | 111 (71.6) | 97 (70.3) | 89 (67.9) | 86 (65.6) | 89 (65.9) | 84 (66.7) | 86 (65.2) |
aMycophenolate: mycophenolate mofetil or mycophenolate sodium
bPrednisone-equivalent per day. Denominator for this category is the number of patients with ≥ 1 oral corticosteroid in the time period
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; IV, intravenous; NSAID, nonsteroidal anti-inflammatory drug